Aphria Partners with Schroll Medical

Cannabis Investing News

Aphria (TSX:APH) has announced it has entered into a strategic partnership with Schroll Medical. As quoted in the press release: The Partnership will pursue the cultivation and worldwide distribution of organic, EU GMP-certified medical cannabis, and will be managed by the Company’s wholly-owned subsidiary Aphria Deutschland GmbH (“Aphria Germany“). The deal accelerates Aphria’s global expansion, …

Aphria (TSX:APH) has announced it has entered into a strategic partnership with Schroll Medical.

As quoted in the press release:

The Partnership will pursue the cultivation and worldwide distribution of organic, EU GMP-certified medical cannabis, and will be managed by the Company’s wholly-owned subsidiary Aphria Deutschland GmbH (“Aphria Germany“). The deal accelerates Aphria’s global expansion, in collaboration with an established and world-class partner, with first product expected to be available by early 2019.

“Aphria continues to execute on its strategy for international expansion, and we are pleased to have joined forces with a highly-regarded, experienced grower known around the world for its quality,” said  Vic Neufeld Chief Executive Officer at Aphria. “Our co-founders come from the world of commercial agriculture, including commercial flower production, so we speak the same language as Schroll and we bring to this Partnership the best-in-class know-how to produce high-quality, clean and pure medical cannabis for the worldwide market. Partnerships such as this continue to build upon Aphria’s foundation for long-term sustained growth in every market in which we operate.”

In exchange for a 15% interest in the Partnership, Aphria is providing €100,000 to the Partnership, its leadership in cannabis greenhouse cultivation and experience in processing and worldwide distribution. This will include, but is not limited to, consulting on GMP certification, cannabis genetics and strains, and proprietary growing IP. Aphria will also handle the worldwide distribution of medical cannabis produced by the Partnership, which is anticipated to be made available to markets in GermanyLuxembourgSwitzerland and other developing medical cannabis markets. As part of the deal, Aphria maintains a path to increase its ownership interest to 50% and a path to realize full liquidity, each under certain conditions.

Click here to read the full press release.

The Conversation (0)
×